NEWS HIGHLIGHTS
Published Studies Related to Firmagon (Degarelix)
Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal
therapy for patients with locally advanced prostate cancer. [2013] Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone
antagonist, representing one of the latest additions to androgen deprivation
therapy (ADT). ADT is used as first-line therapy for locally advanced or
metastatic prostate cancer with the aim to reduce testosterone to castrate
levels...
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of
lower urinary tract symptoms secondary to prostate cancer: results from a phase
IIIb study (NCT00831233). [2013] prostate cancer (PrCa)... CONCLUSION: In 40 men with predominantly locally advanced PrCa and highly
Efficacy and safety of androgen deprivation therapy after switching from monthly
leuprolide to monthly degarelix in patients with prostate cancer. [2011] testosterone suppression or safety profile during the first 3 months... CONCLUSIONS: This 3-month analysis indicates that patients with prostate cancer
Cardiovascular safety of degarelix: results from a 12-month, comparative,
randomized, open label, parallel group phase III trial in patients with prostate
cancer. [2010] gonadotropin-releasing hormone antagonist... CONCLUSIONS: In men with prostate cancer degarelix and leuprolide have similar
Degarelix. [2009] Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that, in common with GnRH receptor agonists (e.g. leuprolide, goserelin and triptorelin), is indicated for use as an androgen-deprivation therapy in patients with advanced prostate cancer...
Clinical Trials Related to Firmagon (Degarelix)
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy [Completed]
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486
CS21A study. The study continued until all non-discontinued participants had received
treatment for at least 5 years.
Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients [Completed]
The purpose of this trial was to find an optimal dose for a new trial drug - degarelix
(FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was
studied. Patients participating were treated with FE200486 on one occasion. Thereafter they
came in for visits following a specific schedule until blood samples showed that there was
no further effect.
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients [Terminated]
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients [Terminated]
Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity
to continue treatment with degarelix under a clinical study until FE200486 was available on
the market or until the study was discontinued.
Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of
FE200486.
A Degarelix Trial in Patients With Prostate Cancer [Terminated]
A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot
with the established therapy Zoladex 3 month implant in patients with prostate cancer.
Reports of Suspected Firmagon (Degarelix) Side Effects
Injection Site Pain (14),
Fatigue (13),
Asthenia (12),
Injection Site Erythema (11),
Pyrexia (10),
Abdominal Pain (8),
Headache (8),
Dyspnoea (7),
Malaise (6),
Palpitations (6), more >>
|